EGF, epidermal growth factor, 1950

N. diseases: 774; N. variants: 33
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE However, mesothelin, fibroblast activation protein, epidermal growth factor receptor, carcinoembryonic antigen, disialoganglioside‑2 and human epidermal growth factor 2 are among the main targets of CART‑cell therapy in the case of other types of solid tumors. 30542701 2018
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE HER3 is a member of the epidermal growth factor family and was predominantly described as a negative prognostic factor in various solid tumors as well as in ovarian cancer. 27913862 2017
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Tumor invasion through a basement membrane is one of the earliest steps in metastasis, and growth factors, such as Epidermal Growth Factor (EGF) and Hepatocyte Growth Factor (HGF), stimulate this process in a majority of solid tumors. 28978320 2017
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 AlteredExpression phenotype BEFREE In addition, epidermal growth factor (EGF) signaling pathway modulates the expression of claudins in a number of solid tumors. 28160565 2017
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Control of solid tumor growth in mice using EGF receptor-targeted RNA replicase-based plasmid DNA. 22296186 2012
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Overexpression of the EGF receptor (EGFR) is a characteristic finding in a considerable number of solid tumors and often signalizes poor prognosis. 18519753 2008
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Tyrosine kinase with immunoglobulin and epidermal growth factor homology domain-2 (Tie2) has been considered as a rational target for gene therapy in solid tumors. 18330476 2008
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE In searching for EGF target genes, we have identified ERG1.2, the mouse homolog of the solid tumor-associated gene STAG1. 14639658 2003
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 AlteredExpression phenotype BEFREE These results demonstrate the potent anti-tumor activity of ABX-EGF and its therapeutic potential for the treatment of multiple human solid tumors that overexpress EGFr. 11255078 2001
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Trastuzumab (Herceptin) is the first monoclonal antibody to be approved for the treatment of a solid tumour and is directed against the c-erb-B2 receptor. c-erb-B2 is a member of the epidermal growth factor family and approximately 25% of breast cancers express such receptors, which appear to confer a poorer prognosis and may be an indicator of resistance to cytotoxic chemotherapy. 11824879 2001
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 AlteredExpression phenotype BEFREE The co-occurrence of Her-2/neu overexpression and EGF receptor overexpression in the same aneuploid cells defines an adeno/squamous genetic evolutionary sequence that is common to ductal breast cancers, non-small cell lung cancers, and other solid tumors. 9298807 1997